K-001 Treatment of Advanced Pancreatic Cancer: Clinical Trial of Monotherapy's Tolerability

NCT02720666 ↗

Phase 1 Completed 12 enrolled Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study is an open and single-center Phase I clinical research on patients with advanced pancreatic cancer, for evaluating their adverse reactions or tolerance to K-001, so as to determine the safe and reasonable dosage and dosing regimen.

Timeline

Start: 2016-01
Primary completion: 2016-12
Completion: 2016-12

Publications

Cui J, Yang H, Liu J, Chen D, Hu J, Zhang H, Wang Y, Han T, Mao T, Jiao F, Biskup E, Pan Y, Liu M, Wang L. A phase I study of the safety and activity of K-001 in patients with advanced pancreatic ductal adenocarcinoma. BMC Cancer. 2021 Jun 7;21(1):672. doi: 10.1186/s12885-021-08375-6.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	K-001	Other / unclassified	1350 mg	Oral
Subject	K-001	Other / unclassified	1620 mg	Oral
Subject	K-001	Other / unclassified	1890 mg	Oral
Subject	K-001	Other / unclassified	2160 mg	Oral

K-001 Treatment of Advanced Pancreatic Cancer: Clinical Trial of Monotherapy's Tolerability

Summary

Timeline

Publications

Drugs

Indications